GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
2022-12-07| M&A

European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment

by Reed Slater
Share To

After Illumina completed its acquisition of a cancer-detection company, Grail, in August last year, European regulators decided to prohibit the merger in September this year, citing concerns of Illumina stifling competition in the cancer-detection market. On Monday, the European Commission (EC) released a Statement of Objections outlining its demands to reverse the acquisition to return equilibrium to the biotech market. 

The Controversial Merger

Despite completing the acquisition in August last year, Illumina is saddled with lawsuits from regulatory bodies against the deal. The first came from the Federal Trade Commission (FTC) in March last year, months before the deal closed. After fighting back and forth in high courts, Illumina came out on top when an administrative law judge ruled in favor of the big pharma company. 

The FTC initially brought the lawsuit to light for the same concerns the EC has. The primary concerns revolve around Grail’s multicancer early detection (MCED) tests and Illumina’s potential ability to stifle competition in the field following the acquisition. 

Illumina holds a different view on the matter, though, saying the merger will get Grail’s proprietary MCED test, Galleri, to patients much faster and cheaper than Grail could on its own. The company estimated that accelerating access to Galleri could save approximately 10,000 lives over nine years. 

Still, the EC continues to pursue the merger under the EU Merger Regulation after opening an in-depth investigation into the matter in July last year. Over a year later, Illumina is still fighting back and does not seem to have plans to stop or reverse the acquisition.

Related Article: European Commission Prohibits Illumina’s Acquisition of GRAIL After The Company’s Win Against The FTC

The EC’s Demands to Unwind the Deal

Despite the EC’s review, Illumina went on with the merger, much to the ire of the regulatory body. With the September prohibition, the EC is demanding that Illumina unwind the acquisition to restore the EC’s initial prohibition decision.

The EC has three major measures it wants to see from Illumina to dissolve the transaction. First, Illumina must restore Grail’s independence from Illumina to its original state before the acquisition. Next, Grail must be as viable and competitive as it was before Illumina’s dealings with the company. Last, the EC ordered the divestment to be “swift and with sufficient certainty,” so the transaction is restored promptly.

It will take more than just the Statement of Objections for Illumina to start reversing the $7.1 billion deal. According to Reuters, the company said it believes divestment is not proportional to the allegations placed by the EC. Illumina also said the EC should hold off on any divestment orders until European courts settle its prohibition appeal. 

Illumina’s rocky Grail acquisition is sure to face more turbulence in the coming months and potentially years as regulatory bodies express concerns over the deal’s impact on competition in the cancer-detection test market. The EC’s most recent Statement of Objections is significant in the process, but Illumina is fighting back with all its might to bring Grail entirely under its wing. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top